KIORA PHARMACEUTICALS INC (KPRX) - Dilution Analysis

S-3 filing: The company is registering for resale by selling stockholders an aggregate of 11,797,088 shares of common stock, including shares issued in a private placement and shares underlying pre-funded and Tranche A-1 and A-2 warrants.

10-Q filing | 4.2M shares outstanding

8-K filing: Kiora Pharmaceuticals, Inc. completed a private placement on April 6, 2026, issuing shares and warrants to institutional investors for gross proceeds of approximately $5.0 million and potential future warrant exercise gross proceeds of approximately $19.0 million. ($5.0M proceeds)

10-K filing | 4.1M shares outstanding

10-Q filing | 3.7M shares outstanding

10-Q filing | 3.4M shares outstanding

10-Q filing | 3.0M shares outstanding

10-K filing | 3.0M shares outstanding

10-Q filing | 3.0M shares outstanding

10-Q filing | 3.0M shares outstanding

8-K filing: Stock split 1-for-9 | Outstanding: 25,936,163 → 2,970,568

10-Q filing | 25.9M shares outstanding

10-K filing | 26.3M shares outstanding

S-3 filing: The filing is an S-3 registration statement for the resale of 76,528,829 shares of common stock by selling stockholders.

8-K filing: Kiora Pharmaceuticals, Inc. entered into a securities purchase agreement to issue and sell 15,800,000 shares of common stock, pre-funded warrants to purchase up to 11,354,237 shares of common stock, Tranche A warrants to purchase up to 24,687,295 shares of common stock, and Tranche B warrants to purchase up to 24,687,295 shares of common stock for gross proceeds of approximately $15.0 million and potential future warrant exercise gross proceeds of approximately $30.0 million. ($15.0M proceeds)

10-Q filing | 7.1M shares outstanding

10-Q filing | 7.2M shares outstanding

8-K filing: Kiora Pharmaceuticals closed a public offering on June 6, 2023, issuing common stock, preferred stock, and warrants, with net proceeds of approximately $5.6 million; also filed a Certificate of Designation for Series F Convertible Preferred Stock.

S-1/A filing: This is an S-1/A filing for an offering of common stock, Series F Preferred Stock, Class C Warrants, and Class D Warrants. The company intends to use the net proceeds from this offering to support its operations, including for clinical trials, for working capital and for other general corporate purposes.

S-1/A filing: This S-1/A filing includes information on the offering of 5,905,512 shares of common stock, 15,000 shares of Series F Preferred Stock convertible into common stock, and warrants to purchase up to 2,952,756 shares of common stock.

10-Q filing | 1.9M shares outstanding

10-K filing | 1.9M shares outstanding

8-K filing: Kiora Pharmaceuticals entered into a securities purchase agreement with Lincoln Park Capital Fund, LLC for the issuance and sale of 52,798 shares of common stock and warrants to purchase up to 105,596 shares, and also entered into a purchase agreement with Lincoln Park for the potential sale of up to $10.0 million of common stock over a 36-month period. ($0.2M proceeds)

S-1 filing: This S-1 filing relates to the offer and sale of up to 1,052,798 shares of common stock by the selling stockholder, Lincoln Park Capital Fund, LLC.

S-1 filing: Registration for resale of 654,610 shares of common stock issuable upon exercise of warrants issued in a private placement.

8-K filing: Kiora Pharmaceuticals consummated a registered public offering on July 26, 2022, issuing shares of common stock, preferred stock, and warrants, and on November 17, 2022, the company entered into warrant exercise inducement letters, expecting to receive $3.12 million in gross proceeds. ($3.12M proceeds)

10-Q filing | 1.1M shares outstanding

10-Q filing | 13.1M shares outstanding

8-K filing: Kiora Pharmaceuticals closed a public offering on July 26, 2022, issuing and selling 23,695,697 shares of common stock, 1,280 shares of Series E Convertible Preferred Stock, 30,095,697 Class A Warrants, and 30,095,697 Class B Warrants, with net proceeds to the company of approximately $5.3 million.

S-1/A filing: This S-1/A filing includes an offering of common stock, Series E Preferred Stock convertible into common stock, Class A Warrants and Class B Warrants, with the intention to use the net proceeds for operations, including clinical trials, working capital and other general corporate purposes.

S-1/A filing: This S-1/A filing includes information about common stock, Series E Convertible Preferred Stock, and warrants to purchase common stock, along with details on voting rights, dividends, liquidation rights, and other rights and preferences. The offering involves 26,170,172 shares of common stock, 6,950.80 shares of Series E Preferred Stock convertible into 26,170,172 shares of common stock, and warrants to purchase up to 26,170,172 shares of common stock.

S-1/A filing: This S-1/A filing registers the offering of common stock, Series E Preferred Stock convertible into common stock, and warrants to purchase common stock.

10-Q filing | 13.1M shares outstanding

S-1 filing: The filing is an S-1 form for an offering of common stock, Series E Convertible Preferred Stock, and warrants.

10-K filing | 12.7M shares outstanding

10-Q filing | 12.6M shares outstanding

10-Q filing | 7.1M shares outstanding

8-K filing: EyeGate Pharmaceuticals, Inc. sold 4,668,844 shares of common stock at $2.3025 per share and unregistered warrants to purchase up to 2,334,422 shares of common stock at an exercise price of $2.24 per share in a registered direct offering, with gross proceeds expected to be approximately $10.75 million. ($10.75M proceeds)

10-Q filing | 7.1M shares outstanding

S-3 filing: This S-3 filing relates to the possible resale of 3,931,112 shares of common stock by selling stockholders.

10-K filing | 7.1M shares outstanding

8-K filing: EyeGate Pharmaceuticals, Inc. entered into a Securities Purchase Agreement to issue 1,531,101 shares of its common stock and warrants to purchase 1,531,101 shares of common stock to Armistice Capital Master Fund, Ltd. in a private placement for a combined purchase price of $5.225 per Share and Warrant.

10-Q filing | 4.6M shares outstanding

10-Q filing | 4.6M shares outstanding

10-Q filing | 4.5M shares outstanding

10-K filing | 4.6M shares outstanding

8-K filing: EyeGate Pharmaceuticals, Inc. entered into a Securities Purchase Agreement for the issuance of 500,000 shares of common stock at $10.00 per share, with expected total gross proceeds of $5.0 million. ($5.0M proceeds)